Overcoming Immune Resistance With Radiation Therapy in Prostate Cancer

Prostate cancer is the second most common cancer in men and represents a significant healthcare burden worldwide. Therapeutic options in the metastatic castration-resistant setting remain limited, despite advances in androgen deprivation therapy, precision medicine and targeted therapies. In this re...

Descripción completa

Detalles Bibliográficos
Autores principales: Mulvey, Arthur, Muggeo-Bertin, Emilien, Berthold, Dominik R., Herrera, Fernanda G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9115849/
https://www.ncbi.nlm.nih.gov/pubmed/35603186
http://dx.doi.org/10.3389/fimmu.2022.859785

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9115849/
https://www.ncbi.nlm.nih.gov/pubmed/35603186
http://dx.doi.org/10.3389/fimmu.2022.859785

Ejemplares similares